HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers
| Autor: | Samuel L. Cytryn, Yelena Y. Janjigian |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Journal of the National Comprehensive Cancer Network. 21:423-429 |
| ISSN: | 1540-1413 1540-1405 |
| DOI: | 10.6004/jnccn.2023.7010 |
| Popis: | HER2 is overexpressed in approximately 20% of esophagogastric cancer (EGC) cases. The addition of the anti-HER2 antibody, trastuzumab, to chemotherapy in 2010 was the first targeted treatment to demonstrate an improvement in survival. The aggressive nature and heterogeneous biology of EGC have posed a particular challenge and resulted in numerous negative trials without a change in standard of care for more than a decade. However, with the incorporation of dual HER2 and PD-1 blockade as well as the advent of a new, potent antibody–drug conjugate, trastuzumab deruxtecan, there have been 2 new FDA approvals for this patient population within the past 2 years. Consequently, the management and landscape of HER2-positive EGC is rapidly changing and increasingly optimistic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|